Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1454-1460

  Kim, Yu Jin ^a   Paik, Seung Woon ^a   Sinn, Dong Hyun ^a   Gwak, Geum Youn ^a   Choi, Moon Seok ^a   Lee, Joon Hyeok ^a   Koh, Kwang Cheol ^a   Yoo, Byung Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Lamivudine resistance

Indexed keywords

ADEFOVIR; CREATININE; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; COMPLETE VIROLOGICAL RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; SIDE EFFECT; TREATMENT OUTCOME; VIRAL PHENOMENA AND FUNCTIONS;

EID: 84865368029     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07050.x     Document Type: Article

References (35)

1. Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int. 2010; 30: 657-68.
2. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-63.
3. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-8.
4. Schalm SW, Heathcote J, Cianciara J etal. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-8.
5. Chang TT, Lai CL, Chien RN etal. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004; 19: 1276-82.
6. Lok AS, Lai CL, Leung N etal. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
7. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
8. Bartholomew MM, Jansen RW, Jeffers LJ etal. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2.
9. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.
10. Dienstag JL, Goldin RD, Heathcote EJ etal. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
11. Lee YS, Suh DJ, Lim YS etal. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-91.
12. Yeon JE, Yoo W, Hong SP etal. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-95.
13. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
15. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
16. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
17. Perrillo R, Hann HW, Mutimer D etal. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
18. Pellicelli AM, Barbaro G, Francavilla R etal. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin. Ther. 2008; 30: 317-23.
19. Kim HJ, Park JH, Park DI etal. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J. Gastroenterol. Hepatol. 2010; 25: 1374-80.
20. Ryu HJ, Lee JM, Ahn SH etal. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J. Med. Virol. 2010; 82: 1835-42.
21. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
22. Inoue J, Ueno Y, Wakui Y etal. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J. Viral Hepat. 2011; 18: 206-15.
23. Yatsuji H, Suzuki F, Sezaki H etal. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol. 2008; 48: 923-31.
24. Chung GE, Kim W, Lee KL etal. Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamivudine-resistant chronic hepatitis B. Dig. Dis. Sci. 2011; 56: 2130-36.
25. Shin SR, Yoo BC, Choi MS etal. A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B. Hepatol. Int. 2011; 5: 664-70.
26. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J. Gastroenterol. Hepatol. 2011; 26: 138-43.
27. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin. Liver Dis. 2006; 26: 142-52.
28. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
29. Keeffe EB, Zeuzem S, Koff RS etal. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2007; 5: 890-7.
30. van Bömmel F, Zöllner B, Sarrazin C etal. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-25.
31. Berg T, Marcellin P, Zoulim F etal. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic hepatitis B virus infection. Gastroenterology 2010; 139: 1207-17.
32. Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment. Pharmacol. Ther. 2011; 34: 972-81.
33. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic are of hepatitis B virus infection. Intervirology 2005; 48: 133-7.
34. Cho JH, Yoon KH, Lee KE etal. Distribution of hepatitis B virus genotypes in Korea. Korean J. Hepatol. 2009; 15: 140-7.
35. Lee JM, Park JY, Kim do Y etal. Long-term adefovir dipivoxil monotherapy for up to 5years in lamivudineresistant chronic hepatitis B. Antivir. Ther. (Lond.) 2010; 15: 235-41.